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Abstract 
 
OBJECTIVE:  The objective of this selective EBM review is to determine whether or not the use 
of curcumin, versus a placebo, is effective in changing cognitive function. 
 
STUDY DESIGN: Review of 3 randomized control trials with blinding in English from 2008 to 
present.  
 
DATA SOURCES: Articles were selected from Cochrane and PubMed databases based on 
relevance to the selected research question and patient-centered outcomes.  
 
OUTCOME(S) MEASURED: The outcome measured is cognitive change, evaluated by mean 
score changes in the Mini Mental Status Examination (MMSE) or the Montreal Cognitive 
Assessment (MoCA).  
 
RESULTS: Two of the studies demonstrated no change in cognitive function measured with the 
MMSE (Ringman JM, Frautschy SA, Teng E, et al. Alzheimers Res Ther. 2012;4(5):43. doi: 
10.1186/alzrt146. and Baum, L, Lam CW, Cheung SK, et al. J Clin Psychopharmocol. 
2008;28(1):110-113. doi: 10.1097/jcp0b013e318160862c), while the third article also did not 
demonstrate a change in cognitive function, as measured by the MoCA (Rainey-Smith SR, 
Brown BM, Sohrabi HR, et al. Br J Nutr. 2016;115(12):2106-2113. doi: 
10.1017/S0007114516001203). 
 
CONCLUSIONS: The studies are unable to demonstrate that curcumin is more effective than 
placebo in preventing cognitive changes.  
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INTRODUCTION 
 
Cognitive decline is a common and heartbreaking symptom, typically caused by certain 
diseases or organic changes in brain structures over time. It can vary in symptomology, ranging 
from short-term memory loss to permanent dementia. In 2011, over 16 million people in the 
United States lived with some degree of cognitive impairment. The most studied and influential 
risk factor for cognitive changes is increasing age. Today, the US population is living longer due 
to the large “Baby Boomer” generation.2 It follows that clinicians will be seeing and treating 
more dementia-related diagnoses than ever before.  
Diseases that cause cognitive decline, such as Alzheimer’s disease or vascular dementia, 
are considered to be the 3rd most costly diseases to treat in the US. In 2010 alone, the US spent 
$3.2 billion for nursing home residents with Alzheimer’s disease, not including the estimated 
$144 billion in expenses for family and volunteer care.1 Healthcare for people with cognitive 
decline costs more than that of heart disease and cancer combined in this country.2 People with 
cognitive impairment are more likely to use healthcare resources, including the emergency 
department and family practices, more frequently and more inappropriately than those with other 
diagnoses.2 These patients also utilize family members to care and advocate for them, causing an 
emotional, physical, and monetary cost that, while not easily described, is significant and 
potentially overwhelming for many caregivers.  
The definitive cause of cognitive decline, especially in its most common form of 
Alzheimer’s disease, is still unknown. However, some researchers hypothesize that structural 
brain changes over time and the formation of beta-amyloid plaques, neurofibrillary tangles, and 
tau proteins are to blame for the cognitive symptoms and mood disorders commonly associated 
with dementia.3 Declines in cognitive function are unfortunately nonspecific, but typically 
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include symptoms like memory loss, vision change, mood or behavior change, and decreased 
recognition or memory recall. There are currently no medications approved by the FDA to treat 
dementia.4 However, some off-label therapies that are commonly used to treat Alzheimer’s 
disease are cholinesterase inhibitors, benzodiazepines, lifestyle changes, and treatment of any 
underlying organic cause.4 
Currently, there are not many effective, safe, or well-studied options for treating or 
reversing idiopathic cognitive changes. This reality forces patients and family members to find 
treatment and relief with more natural substitutes. A diet change is one of the more popular 
alternatives to medication for people with cognitive changes. One of these dietary alterations is 
to increase parenteral intake of a spice known as curcumin.  More commonly known as turmeric, 
it is found in many eastern diets including Indian curry and Thai soups. Turmeric has colloquial 
benefits reported from these cultures for many different illnesses and symptoms. Curcumin has 
also been shown to have important antioxidant and anti-inflammatory effects, while also having 
a positive influence on cognition, especially in animal studies.5,6 This systematic review 
evaluates the ability of the spice curcumin to change cognitive function and reverse cognitive 
decline in older adults.  
OBJECTIVE 
The objective of this selective evidence-based medicine (EBM) review is to determine if the 
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METHODS 
 The studies used in this EBM review were found and selected using PubMed and 
Cochrane Library databases. The objective was to find three randomized control trials (RCTs) 
from peer-reviewed journals that included adults over the age of 40 with changes in cognitive 
function. They had to be relevant to clinical practice and had to measure patient-oriented 
outcomes. Inclusion criteria for the searches were studies published after 2008, randomized 
control trial, written in English or Spanish, and using human subjects. The exclusion criteria 
were review articles and publication before 2008. 
In each study, the spice curcumin was the intervention of choice. The study by Rainey-
Smith et al.6 used 500 mg Biocurcumax-95 curcumin capsules three times daily, Baum et al.7 
utilized 1 g curcumin powder via capsule or packet once daily, and Ringman et al.5 chose to use 
Curcumin C3 Complex 2 g or 4 g divided into two daily doses. The interventions were compared 
to a placebo that matched the spice’s form and administration method in each study. The major 
outcome measured in these studies was change in cognitive ability measured via the Mini Mental 
Status Examination (MMSE) and Montreal Cognitive Assessment (MoCA).5,6,7 The articles also 
measured outcomes including adverse effects of the spice and bioavailability via plasma and 
CSF levels of curcumin after ingestion; these outcomes, however, are not being evaluated in this 
paper, as they were not universally studied.5,7 Table 1 contains an exhaustive list of inclusion and 
exclusion criteria for the study subjects, as well as more detailed epidemiologic data. Each article 
reported their findings and statistics as p-values from ANOVA of the mean changes in baseline 
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Table 1. Demographics & Characteristics of Included Studies 
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OUTCOMES MEASURED  
Each study measured changes in cognitive abilities using either the MMSE5,7 or the 
MoCA,6 given before the clinical trial began and again at the end of the clinical trial. The MMSE 
is a quick and simple exam given by a health practitioner to quantify a person’s cognitive 
function and over time, evaluate cognitive loss. It measures several aspects of cognition such as 
orientation, naming, attention, calculation, language, motor skills, and recall. The highest score 
possible on the MMSE is 30 points. The MoCA is another exam that health care workers use to 
evaluate the cognitive function of patients. It measures executive and visuospatial function, in 
addition to the cognitive functions the MMSE tests for, with a total score possible of 30 points. 
Both are well-known and accepted screening tools for many diseases that cause cognitive 
decline.  
Two of the trials reevaluated scores after six months5,7 and one performed evaluations 
additionally at twelve months.6 The individual scores were then calculated into means for each 
group, with the appropriate standard deviations; ANOVA and its corresponding p-value was then 
calculated as well.5,6,7 Changes in cognition were also analyzed by changes in activities of daily 
living (ADCS-ADL) and by the ADAS-cog which is an exam specifically for Alzheimer’s 
disease. However, these findings are not compared in this study because they were not utilized 
among all three trials.5  
RESULTS 
 Three randomized control trials compared curcumin supplementation vs. placebo in 
similar form and administration. Two of the studies used subjects who had clinical dementia or 
cognitive deficits,5,7 while the third excluded people with diagnoses of dementia or cognitive 
decline.6 All three studies required the subjects to be at least 40-50 years old, since dementia is 
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an age-related disease. Additionally, the studies each excluded subjects on blood thinners, 
aspirin, or frequent NSAID use because curcumin could potentially interact with these drugs. 
The trial subjects were able to continue to live at home, whether independently or in a care-home 
setting throughout the study. They had to present to the study headquarters for medication refills 
and health questionnaires during either the six or twelve months, depending on the study. Only 
one study, by Ringman et al.,5 retained enough subjects to have a losses-to-follow-up ratio of less 
than 20%. A majority of patients withdrew due to gastrointestinal adverse effects in all three of 
the randomized control trials and there were no serious adverse effects experienced by 
participants in any of the three trials.5,6,7 
In the study by Ringman et al.,5 thirty-six subjects with mild to moderate cognitive 
dysfunction were randomized into three different groups; one group received placebo (n=11), 
while the other two received either 2g (n=9) or 4g (n=10) of curcumin intervention for twenty-
four weeks.5 The outcomes measured were drug tolerability and cognitive changes, via subject 
interviews or MMSE scores, respectively.5 Six of the subjects withdrew; one due to significant 
memory changes and the other five withdrew because of adverse effects of the intervention 
medication.5  Each group had roughly equal numbers of men and women, education levels, and 
current use of memantine for dementia.5 Interestingly, the placebo group (70.2 yrs.) was five to 
six years younger than either intervention group (76.7 and 75.3 yrs.).5 There was no significant 
difference in change in MMSE scores using ANOVA calculations.5 However, when both the 2 g 
and 4 g curcumin groups were combined and compared to the placebo group, there was a trend 
for the intervention groups to perform worse than the placebo group.5 While being an interesting 
trend, the change is not significant with a p-value of 0.08, nor does it exist when each individual 
curcumin group is compared to placebo, as seen in table 2.5  
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Table 2. MMSE Results Measuring Cognitive Change for Ringman et al.5  
Mean 
Baseline 























22.8 23.2 19.9 22.7 -2.90 -0.45 0.08 
 
 The Rainey-Smith et al.6 RCT enrolled 160 community-dwelling older adults without a 
current diagnosis of dementia or cognitive dysfunction and randomized them into two groups 
receiving placebo or 1.5 g of curcumin in divided doses daily for 12 months.6 The study included 
results of only ninety-six participants, as forty-nine withdrew due to adverse effects and fifteen 
others were non-compliant with their regimen.6 There were no significant differences between 
the two groups in terms of demographic information, including age, sex, medical history, or 
education level.6 At baseline, the placebo group performed better on the MoCA significantly, as 
indicated by a p-value < 0.05. At six and twelve months, the score changes were analyzed by 
repeated-measures ANOVA.6 Interestingly, at six months, the placebo group had a score 
decrease that was then annulled at the twelve-month reading, which was not seen in the treatment 
group.6 Therefore, the time x treatment analysis shows a significant improvement for the 
curcumin group with a p-value < 0.05.6 When comparing only the baseline scores to the final 
twelve-month scores and isolating the time variable, however, there was no significant change, 
as seen in table 3.6  




























25.8 26.4 26.5 26.5 0.64 0.09 0.25 
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Baum et al.7 created a study that enrolled 34 subjects with mild cognitive decline to take 
either placebo, 1 g of curcumin, or 4 g of curcumin for six months. While the subjects were 
matched across the three groups regarding medical history, there were more females enrolled and 
the placebo group was significantly older than either intervention group at 77.8 years of age.7 All 
participants were of Asian descent.7 Seven of the participants withdrew due to gastrointestinal 
complaints, falls, or respiratory tract infections.7 Mean change in MMSE scores was not 
significant, as shown in table 4.7 Even when combining the two intervention groups’ data and 
comparing that average to that of the placebo group, there was still not a significant change with 
p=0.39.7  
Table 4. MMSE Results for Baum et al. Study7  
Mean Change from 
Baseline (C=1 g) 
Mean Change from 
Baseline (C=4 g) 
Mean Change 
from Baseline (P) 
P-Value 




 Cognitive decline, whether due to vascular dementia, Alzheimer’s disease, or Parkinson’s 
disease, is a significant and debilitating symptom affecting a person’s ability to think, move, and 
live independently. Unfortunately, there are no FDA approved drugs or treatment regimens for 
cognitive decline.4 Current recommendations include trials of grade 2A cholinesterase inhibitors 
such as donepezil or rivastigmine, followed by memantine for more significant dementia or 
decline.8 Diet additives like ginkgo biloba, vitamin B, and omega-3 fatty acids have unproven 
benefits for dementia and are patient-specific.8 Trials of new dietary supplements or medications 
continue to be necessary until a proven treatment for cognitive decline is found.  
Curcumin, also known as turmeric, is an inexpensive and well-known spice that is 
currently being researched for its efficacy. It has been shown to have anti-oxidant and anti-
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inflammatory benefits, and some people have relief from arthritis and muscle pain with its use.9 
The Joint United Nations and World Health Organization Expert Committee on Food Additives 
reports the acceptable daily intake (ADI) of curcumin to be 0-3 mg/kg, and considers curcumin 
to be a safe additive, with minor side effects including nausea, diarrhea, or headaches at high 
intake levels.9  All three articles researched for this paper had some level of adverse effects 
consistent with diarrhea, nausea, or other gastrointestinal upset for subjects on the intervention 
drug.5,6,7 Compared to anticholinergics or benzodiazepines, with high side effect profiles and 
sedating qualities, curcumin seems to be a more attractive alternative for many patients. 
While these articles were randomized and all were at least single-blinded, there are some 
aspects of validity that are concerning. The Baum7 study had a placebo group older than the 
experimental group, while the Ringman5 study had a significantly younger placebo group 
compared to the experimental group. Since age is the greatest risk factor for cognitive decline, it 
makes it difficult to accept the final results of the studies if there are significant age differences 
between subject groups. The two studies do not show opposing results even though their control 
group ages were different. This could mean 5-7 years difference in age is not a significant 
variable, or it could be damaging to validity. 
  Only two of the trials, by Ringman5 and Baum7 included patients with existing cognitive 
decline. However, their results did not differ from the trial that only included healthy subjects, 
see tables 2-4.5,6,7 The Ringman5 study was the only one to maintain a loss-to-follow-up ratio less 
than 20% and have a relatively large sample size with 160 subjects randomized. Much potential 
data was lost because of poor subject compliance that could have affected the final results in all 
three trials. Unfortunately, none of the articles offered “worst-case” analysis for the subjects that 
were lost. Additionally, none of the articles mentioned how they controlled for normal dietary 
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intake of curcumin in the control groups. This variable could have had significant impacts 
specifically in the Baum study because all the subjects were Hong Kong Chinese and most likely 
use turmeric regularly in their diets.7  
 The most significant factor affecting these studies, however, is that curcumin has low 
bioavailability and poor gastric absorption.5 Even though each article used a different version of 
curcumin powder, it was still a generally pure derivative of curcumin without other additives or 
chemical components.5,6,7  
CONCLUSIONS 
 The three clinical trials analyzed do not establish that curcumin is effective in reducing 
cognitive decline when compared against placebo. Each study showed similar cognitive changes 
when analyzing MMSE or MoCA score changes after six or twelve months.5,6,7 However, this 
does not mean that curcumin should be rejected as a potential treatment for cognitive changes. 
Each article showed low plasma absorption of curcumin, which further demonstrates that 
curcumin alone is not absorbed well by humans.5,6 While finding subjects for medical trials is 
difficult, futures studies should do a better job accounting for losses to follow up, creating 
groupings that are demographically similar, and demonstrating control over variables from daily 
life that could influence results. In the future, researchers should try an intervention that 
supplements curcumin to enable better absorption, such as piperine or turmeric, the spice from 
which pure curcumin is derived from.9  It would be beneficial to also evaluate if long-term use of 
curcumin in healthy young adults can prevent future cognitive decline, unlike many current study 
patterns. Creating more studies that utilize a bioavailable version of curcumin or that evaluate 
long-term use of curcumin could potentially ameliorate cognitive decline or prevent it from 
occurring in the first place.  
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